NeoLATC
Recruiting
120 enrolled
ALCG-01
Recruiting
400 enrolled
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Recruiting
30 enrolled
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
Completed
70 enrolled
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Completed
260 enrolled
International Multicentric Study ARON-1
Recruiting
1,220 enrolled
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Recruiting
20 enrolled
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Completed
100 enrolled
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Completed
327 enrolled
SURROGATE-ICI
Completed
631 enrolled 6 charts
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Completed
662 enrolled
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Recruiting
270 enrolled
A Benefit Population Atlas of nICT Versus nCT for LAGC
Completed
291 enrolled
ProNiHN
Completed
502 enrolled
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Active not recruiting
100 enrolled
URADJ
Terminated
176 enrolled
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
Completed
64 enrolled
DELINOR
Completed
5,279 enrolled 10 charts
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Active not recruiting
100 enrolled
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
Completed
150 enrolled
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
Completed
101 enrolled
METAGIO
Recruiting
500 enrolled
The Immune Assessment of PD-1 Antibody Therapy in Tumor
Recruiting
3,000 enrolled
APiTOXMM
Recruiting
160 enrolled
Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
Terminated
19 enrolled
EROS
Recruiting
80 enrolled
Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
Completed
250 enrolled
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
Completed
700 enrolled
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Completed
600 enrolled
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Unknown
585 enrolled
TREATMENT
Unknown
200 enrolled
I-STOP
Unknown
300 enrolled
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Completed
1,864 enrolled 12 charts
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
Completed
1,975 enrolled
ST-ICI
Completed
150 enrolled
Microbiome Immunotherapy Toxicity and Response Evaluation
Unknown
1,800 enrolled
QUASAR
Unknown
42 enrolled
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
Completed
87 enrolled
VOLUME-PRO
Completed
509 enrolled
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
Unknown
300 enrolled
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Unknown
400 enrolled
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Unknown
100 enrolled
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients
Completed
60 enrolled
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Unknown
130 enrolled
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Unknown
30 enrolled
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Unknown
4,724 enrolled
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
Unknown
1,000 enrolled
Polish Microbiome Map
Unknown
1,160 enrolled
NIVEX
Completed
676 enrolled
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Unknown
50 enrolled